| Target Validation Information | |||||
|---|---|---|---|---|---|
| TTD ID | T50942 | ||||
| Target Name | Low-affinity nerve growth factor receptor (NGFR) | ||||
| Type of Target |
Successful |
||||
| Action against Disease Model | Tanezumab | Drug Info | Tanez uMab and its murine precursor m uMab-911 effectively targeted the NGF pathway in various chronic and inflammatory pain models. | [1] | |
| References | |||||
| REF 1 | Tanezumab, a recombinant humanized mAb against nerve growth factor for the treatment of acute and chronic pain. Curr Opin Mol Ther. 2010 Feb;12(1):94-106. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.